Sugi Predict

Sugi Predict / Targets / NLN

NLN

Neurolysin, mitochondrial · Q9BYT8 · NLN on Sugi Atlas →

2,177 patent compounds predicted against NLN, 1,130 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL4308250 SCHEMBL4308250 0.53 5/20
SCHEMBL632158 SCHEMBL632158 0.50 5/20
SCHEMBL16836933 SCHEMBL16836933 0.50 5/20
SCHEMBL632295 SCHEMBL632295 0.49 5/20
SCHEMBL16658481 SCHEMBL16658481 0.58 4/20
SCHEMBL10252727 SCHEMBL10252727 0.50 4/20
SCHEMBL9668538 SCHEMBL9668538 0.48 4/20
SCHEMBL14444082 SCHEMBL14444082 0.64 3/20
SCHEMBL632088 SCHEMBL632088 0.61 3/20
SCHEMBL3632930 SCHEMBL3632930 0.54 3/20
SCHEMBL11479809 SCHEMBL11479809 0.51 3/20
SCHEMBL9426103 SCHEMBL9426103 0.49 3/20
SCHEMBL606714 SCHEMBL606714 0.49 3/20
SCHEMBL7160645 SCHEMBL7160645 0.48 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL10850484) 0.48 3/20
SCHEMBL10521848 SCHEMBL10521848 0.48 3/20
SCHEMBL7037630 SCHEMBL7037630 0.47 3/20
SCHEMBL16187205 SCHEMBL16187205 0.47 3/20
SCHEMBL4222564 SCHEMBL4222564 0.46 3/20
SCHEMBL11298674 SCHEMBL11298674 0.46 3/20

Clinical trials — most relevant to NLN by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium PHASE4COMPLETED
GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS) PHASE2COMPLETED
Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease PHASE2COMPLETED
Testosterone and Long Pulse Stimulation After SCI PHASE2COMPLETED
Trial of Oxaloacetate in ALS PHASE1COMPLETED
Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D) EARLY_PHASE1COMPLETED
Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia EARLY_PHASE1ACTIVE_NOT_RECRUITING
Drug Repurposing for Mitochondrial Disorders Using iPSCs Derived Neural Cells nanRECRUITING
Tissue Sample Study for Mitochondrial Disorders nanENROLLING_BY_INVITATION
Clinical Value of Plasma Humanin in Acute Kidney Injury nanUNKNOWN
Dynamics of Muscle Mitochondria in Type 2 Diabetes Exercise nanCOMPLETED
Oxygenating the Brain With Laser Therapy nanUNKNOWN
Effect of Ketone Esters in Parkinson's Disease nanCOMPLETED
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy nanCOMPLETED
MItochondrial Diabetes LOw Carb- Diet Study nanCOMPLETED
Testing of NBIA Genes: Analysis of Genetic Heterogeneity and Validation of Mitochondrial Markers for Assessing Causality of Sequence Variants. nanCOMPLETED
Cerebrospinal Fluid Mitochondrial Biomarkers in Ischemic Stroke and Alzheimer Disease nanRECRUITING
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia nanUNKNOWN
Mitochondrial Stress, Brain Imaging, and Epigenetics nanCOMPLETED
Insulin Deprivation on Brain Structure and Function in Humans With Type 1 Diabetes nanCOMPLETED
sCD163 in ALS Patients nanCOMPLETED
Measuring Protein Turnover in Humans Across the Lifespan by Metabolic Labeling With Deuterium Oxide nanRECRUITING
The Natural History of Mitochondrial Diseases nanRECRUITING
Relationship Between Mitochondrial Dysfunction and Fatique in Cancer Patients Following External Beam Radiation Therapy nanCOMPLETED
The Energetic Origin of Neurodegeneration in MS nanCOMPLETED
Health, Economic Analysis and Clinical Aspects of Patients With Neurological Disabilities in Enteral Nutrition With Dedicated Formula. The Role of Nissen's Fundoplication in the Management of Gastroesophageal Reflux nanUNKNOWN
The Fuel and Rhythm (FAR) Phase 2 Study nanCOMPLETED
Nicotinamide Riboside and Mitochondrial Biogenesis nanCOMPLETED
Dynamic Neuroimaging Biomarkers in Huntington's Disease nanCOMPLETED
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a NLN binder may also engage these)

ProteinNameSimilarity
Q5R9V6 — 1.000 Q5R9V6 →
A2VDQ5 — 1.000 A2VDQ5 →
P42675 — 1.000 P42675 →
Q02038 — 1.000 Q02038 →
P42676 — 1.000 P42676 →
Q91YP2 — 0.999 Q91YP2 →
Q949P2 — 0.981 Q949P2 →
Q94AM1 — 0.978 Q94AM1 →
F4KDA5 — 0.973 F4KDA5 →
Q54DD2 — 0.970 Q54DD2 →
NPEPPS Puromycin-sensitive aminopeptidase 0.970 landscape →
F4HTQ1 — 0.970 F4HTQ1 →
Q6CVF7 — 0.970 Q6CVF7 →
A8E657 — 0.970 A8E657 →
Q9UDR5 — 0.969 Q9UDR5 →
Q8C1A5 — 0.968 Q8C1A5 →
Q6IP81 — 0.968 Q6IP81 →
G6PD Glucose-6-phosphate 1-dehydrogenase 0.968 landscape →
Q28479 — 0.967 Q28479 →
Q5RBT4 — 0.967 Q5RBT4 →
ACE2 Angiotensin-converting enzyme 2 0.967 landscape →
Q1JPJ8 — 0.967 Q1JPJ8 →
P12646 — 0.966 P12646 →
Q58DD0 — 0.966 Q58DD0 →
Q502K2 — 0.966 Q502K2 →
O55044 — 0.966 O55044 →
P93648 — 0.966 P93648 →
Q6NUA1 — 0.966 Q6NUA1 →
Q8R0I0 — 0.966 Q8R0I0 →
Q6PB06 — 0.966 Q6PB06 →